Daclizumab adverse effects

A 42-year-old Hispanic woman, with end-stage renal disease, anemia, hypertension, and a history of an anaphylactic reaction to basiliximab, was scheduled to receive a living donor transplant and received basiliximab uneventfully (5). However, owing to donor infection the procedure was cancelled and rescheduled for 2 weeks later. Within 10 minutes after basiliximab reinduction she developed an anaphylactic reaction. In an attempt to find another induction therapy for this patient, skin testing was performed for daclizumab without response. She therefore received full-dose induction with daclizumab before her organ transplant without adverse effect. 

Daclizumab, a humanized antibody directed against the alfa chain of the interleukin-2 receptor, has been used for initial immunosuppression in transplant patients. In a phase III trial in 275 patients who received ciclosporin, glucocorticoids, and daclizumab or placebo, there were no specific adverse effects associated with daclizumab (1). In particular, the cjhokine-release sjmdrome did not occur, and there was no difference in the incidence of fungal or cjhomega-lovirus infections between the two groups. 

Few adverse effects have been reported with basiliximab and daclizumab (see Table 87-4). In clinical trials, these drugs were asso-... 

---